Quantum dot-conjugated Anti-GRP78 scFv inhibits cancer growth in mice

Molecules

Volumn 17, Issue 1, 2012, Pages 796-808

  Xu, Weiming ^a   Liu, Lizhi ^a   Brown, Nicola J ^b   Christian, Sven ^c   Hornby, David ^a  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

^b Academic Surgical Oncology Unit   (United Kingdom)

^c BAYER PHARMA AG   (Germany)

Author keywords

AKT; Breast cancer; GRP78; Nanoparticle; Quantum Dot; ScFv

Indexed keywords

ANTINEOPLASTIC AGENT; HEAT SHOCK PROTEIN; IMMUNOTOXIN; MOLECULAR CHAPERONE GRP78; QUANTUM DOT; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY;

ANIMAL; ARTICLE; BAGG ALBINO MOUSE; BREAST TUMOR; DRUG EFFECT; DRUG SCREENING; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE; HUMAN; IMMUNOLOGY; MALE; METABOLISM; MOLECULARLY TARGETED THERAPY; MOUSE; NUDE MOUSE; PATHOLOGY; PROSTATE TUMOR; TUMOR CELL LINE; TUMOR VOLUME;

ANIMALS; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CELL LINE, TUMOR; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE, DIRECT; HEAT-SHOCK PROTEINS; HUMANS; IMMUNOTOXINS; MALE; MICE; MICE, INBRED BALB C; MICE, NUDE; MOLECULAR TARGETED THERAPY; PROSTATIC NEOPLASMS; QUANTUM DOTS; SINGLE-CHAIN ANTIBODIES; TUMOR BURDEN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84862967037     PISSN: None     EISSN: 14203049     Source Type: Journal    
DOI: 10.3390/molecules17010796     Document Type: Article

References (20)

1. Rogach, A.L. Semiconductor Nanocrystal Quantum Dots: Synthesis, Assembly, Spectroscopy, and Applications; Springer: Wien; New York, NY, USA, 2008; p. 372.
2. Jaiswal, J.K.; Mattoussi, H.; Mauro, J.M.; Simon, S.M. Long-term multiple color imaging of live cells using quantum dot bioconjugates. Nat. Biotechnol. 2003, 21, 47-51. (Pubitemid 36055826)
3. Tada, H.; Higuchi, H.; Wanatabe, T.M.; Ohuchi, N. In vivo real-time tracking of single quantum dots conjugated with monoclonal anti-HER2 antibody in tumors of mice. Cancer Res. 2007, 67, 1138-1144.
4. Nelson, A.L. Antibody fragments: Hope and hype. Mabs 2010, 2, 77-83.
5. Chen, Y.; Zhu, X.; Zhang, X.; Liu, B.; Huang, L. Nanoparticles modified with tumor-targeting scFv deliver siRNA and miRNA for cancer therapy. Mol. Ther. 2010, 18, 1650-1656.
6. Lee, A.S. GRP78 induction in cancer: Therapeutic and prognostic implications. Cancer Res. 2007, 67, 3496-3499. (Pubitemid 46762126)
7. Sato, M.; Yao, V.J.; Arap, W.; Pasqualini, R. GRP78 signaling hub a receptor for targeted tumor therapy. Adv. Genet. 2010, 69, 97-114.
8. Arap, M.A.; Lahdenranta, J.; Mintz, P.J.; Hajitou, A.; Sarkis, A.S.; Arap, W.; Pasqualini, R. Cell surface expression of the stress response chaperone GRP78 enables tumor targeting by circulating ligands. Cancer Cell 2004, 6, 275-284. (Pubitemid 39222040)
9. Xu, W.; Liu, L.; Charles, I.G.; Moncada, S. Nitric oxide induces coupling of mitochondrial signalling with the endoplasmic reticulum stress response. Nat. Cell. Biol. 2004, 6, 1129-1134. (Pubitemid 39468015)
10. Liu, L.; Xu, W. Targeting nitric oxide mediated upregulation of membrane-bound glucose regulated-protein 78 by subtractive single chain Variable Fragment (scFv) phage display. Am. J. Biomed. Sci. 2009, 1, 321-335.
11. Daneshmand, S.; Quek, M.L.; Lin, E.; Lee, C.; Cote, R.J.; Hawes, D.; Cai, J.; Groshen, S.; Lieskovsky, G.; Skinner, D.G.; Lee, A.S.; Pinski, J. Glucose-regulated protein GRP78 is up-regulated in prostate cancer and correlates with recurrence and survival. Hum. Pathol. 2007, 38, 1547-1552. (Pubitemid 47418966)
12. Misra, U.K.; Mowery, Y.; Kaczowka, S.; Pizzo, S.V. Ligation of cancer cell surface GRP78 with antibodies directed against its COOH-terminal domain up-regulates p53 activity and promotes apoptosis. Mol. Cancer Ther. 2009, 8, 1350-1362.
13. Burikhanov, R.; Zhao, Y.; Goswami, A.; Qiu, S.; Schwarze, S.R.; Rangnekar, V.M. The tumor suppressor Par-4 activates an extrinsic pathway for apoptosis. Cell 2009, 138, 377-388.
14. Kelber, J.A.; Panopoulos, A.D.; Shani, G.; Booker, E.C.; Belmonte, J.C.; Vale, W.W.; Gray, P.C. Blockade of Cripto binding to cell surface GRP78 inhibits oncogenic Cripto signaling via MAPK/PI3K and Smad2/3 pathways. Oncogene 2009, 28, 2324-2336.
15. Yung, H.W.; Charnock-Jones, D.S.; Burton, G.J. Regulation of AKT phosphorylation at Ser473 and Thr308 by endoplasmic reticulum stress modulates substrate specificity in a severity dependent manner. PLoS One 2011, 6, e17894.
16. Yoeli-Lerner, M.; Yiu, G.K.; Rabinovitz, I.; Erhardt, P.; Jauliac, S.; Toker, A. Akt blocks breast cancer cell motility and invasion through the transcription factor NFAT. Mol. Cell 2005, 20, 539-550. (Pubitemid 41668639)
17. Hutchinson, J.N.; Cardiff, J.; Jin, R.D.; Woodgett, J.R.; Muller, W.J. Activation of Akt-1 (PKB-alpha) can accelerate ErbB-2-mediated mammary tumorigenesis but suppresses tumor invasion. Cancer Res. 2004, 64, 3171-3178. (Pubitemid 38581419)
18. Loizidou, M.; Seifalian, A.M. Nanotechnology and its applications in surgery. Br. J. Surg. 2010, 97, 463-465.
19. Shiohara, A.; Hoshino, A.; Hanaki, K.; Suzuki, K.; Yamamoto, K. On the cyto-toxicity caused by quantum dots. Microb. Immunol. 2004, 48, 669-675. (Pubitemid 39264940)
20. Michalet, X.; Pinaud, F.F.; Bentolila, L.A.; Tsay, J.M.; Doose, S.; Li, J.J.; Sundaresan, G.; Wu, A.M.; Gambhir, S.S.; Weiss, S. Quantum dots for live cells, in vivo imaging, and diagnostics. Science 2005, 307, 538-544. (Pubitemid 40165671)